

Name of the Issuer:	Metropolis Healthcare Limited	Last updated on	25-Feb-22
1 Type of Issue (IPO / FPO) <i>Source: Prospectus dated April 8, 2019</i>	IPO		
2 Issue Size (Rs. Million)* - Fresh Issue Size (Rs. Millions) - Offer for Sale Component (Rs. Millions) <i>*Source: Final post issue report dated April 16, 2019</i>	12,042.88 (Initial Public Offering of 13,685,095 Equity Shares of face value of Rs. 2 each for cash at a price of Rs. 880 per equity share) NIL 12,042.88		
3 Grade of issue along with name of the rating agency Name Grade <i>Source: Prospectus dated April 8, 2019</i>	Not Applicable Not Applicable		
4 Subscription Level (Number of times) <i>Source: Final post issue report dated April 16, 2019</i> <i>*The above figure is after technical rejections</i>	3.6775*		
5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
Particulars	%		
(i) allotment in the issue ⁽¹⁾	20.44%		
(ii) at the end of 1st Quarter immediately after the listing	21.71%		
(iii) at the end of 1st FY (March 31, 2020)	22.24%		
(iv) at the end of 2nd FY (March 31, 2021)	42.97%		
(v) at the end of 3rd FY (March 31, 2022)*	Not Available		
<i>*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.</i>			
<i>(1) Source: Basis of Allotment. Includes allotment to Anchor Investors and BSE Filings</i>			
6 Financials of the issuer			
			(In Rs. Millions)
Parameters	1st FY (March 31, 2020)	2nd FY (March 31, 2021)	3rd FY (March 31, 2022)*
Income from operations	8,564	9,979.87	Not Available
Net Profit for the period	1,276	1,833.49	Not Available
Paid-up equity share capital	101	102.23	Not Available
Reserves excluding revaluation reserves	5,134	6,963.77	Not Available
<i>*Not available as reporting for the relevant fiscal year has not been completed.</i>			
7 Trading Status in the scrip of the issuer Company's Equity Shares are listed on both the BSE Limited and National Stock Exchange of India Limited The Shares have not been suspended or delisted.			
Particulars	Status		
(i) at the end of 1st FY (March 31, 2020)	Frequently traded		
(ii) at the end of 2nd FY (March 31, 2021)	Frequently traded		
(iii) at the end of 3rd FY (March 31, 2022)*	Not Available		
<i>*Trading status not disclosed as the relevant fiscal year has not been completed.</i>			
8 Change in Directors of issuer from the disclosures in the offer document			
Particulars	Name of the Director	Appointed / Resigned	
(i) at the end of 1st FY (March 31, 2020)	Mr. Mihir Jagdish Doshi Ms. Anita Ramachandran	Resigned Appointed	
(ii) at the end of 2nd FY (March 31, 2021)	NA	NA	
(iii) at the end of 3rd FY (March 31, 2022)*	Not Available	Not Available	
<i>* Changes in Directors not disclosed as the relevant fiscal year has not been completed.</i>			

9 Status of implementation of project/ commencement of commercial production

- (i) as disclosed in the offer document Not applicable
(ii) Actual implementation Not applicable
(iii) Reasons for delay in implementation, if any Not applicable

Not applicable, as the Offer was only an Offer for Sale by Selling Shareholders
Source: Prospectus dated April 8, 2019

10 Status of utilization of issue proceeds

- (i) as disclosed in the offer document Not applicable
(ii) Actual utilization Not applicable
(iii) Reasons for deviation, if any Not applicable

Not applicable, as the Offer was only an Offer for Sale by Selling Shareholders

Source: Prospectus dated April 8, 2019

11 Comments of monitoring agency

(a) Comments on use of funds	Not applicable
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

Not applicable, as the Offer was only an Offer for Sale by Selling Shareholders
Source: Prospectus dated April 8, 2019

12 Pricing Data

Issue Price (Rs.): 880
Designated Stock Exchange: BSE
Listing Date: 15-Apr-19

Price parameters	At close of listing day (April 15, 2019)	At close of 30th calendar day from listing day (May 14, 2019) ⁽¹⁾	At close of 90th calendar day from listing day (July 15, 2019) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2020) ⁽³⁾			
				Closing price	High (during the FY)	Low (during the FY)	
Market Price on BSE		959.55	912.85	1,043.65	1,286.25	2,110.00	904.85
BSE Sensex		38,905.84	37,318.53	38,896.71	29,468.49	42,273.87	25,638.90
S&P BSE Healthcare ⁽⁵⁾		14,505.67	13,452.29	13,012.26	12,148.57	14,663.74	10,947.99

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2021) ⁽³⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2022) ^{(3) (4)}		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	2,241.05	2,344.95	1,150.00	Not Available	Not Available	Not Available
BSE Sensex	49,509.15	52,516.76	27,500.79	Not Available	Not Available	Not Available
S&P BSE Healthcare ⁽⁵⁾	21,328.21	22,464.34	11,878.39	Not Available	Not Available	Not Available

Source: BSE website

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days. Next Trading Day (July 15, 2019) has been considered as July 13, 2019 and July 14, 2019 were trading holidays

(3) High and Low based on intraday prices

(4) Pricing data not disclosed as the relevant fiscal year has not completed

(5) S&P BSE Healthcare index represents the relevant sectoral index of which the Company is also a part

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2020)	At the end of 2nd FY (March 31, 2021)	At the end of 3rd FY (March 31, 2022) ⁽²⁾
EPS	Issuer:			
	Consolidated (Basic)	20.61	25.36	35.97
	Consolidated (Diluted)	20.49	25.25	35.79
	Peer Group:			
	Dr. Lal Pathlabs Limited (Basic)	20.85	27.42	35.33
	Dr. Lal Pathlabs Limited (Diluted)	20.82	27.37	35.25
	Industry Avg:	N.A.	N.A.	N.A.
Price to Earnings Ratio (P/E)	Issuer:			
	Based on Consolidated Basic EPS	42.70	50.72	62.30
	Peer Group:			
	Dr. Lal Pathlabs Limited	50.57	51.11	76.63
	Industry Avg:	50.57	51.11	76.63
NAV per share	Issuer:			
	Consolidated	83.58	103.29	138.23
	Peer Group:			
	Dr. Lal Pathlabs Limited	96.93	123.92	153.10
	Industry Avg:	96.93	123.92	153.10

		Issuer:				
RoNW(%)	Consolidated	24.66%	24.37%	25.95%	Not Available	
	Peer Group:					
	Dr. Lal Pathlabs Limited	21.61%	22.13%	23.17%	Not Available	
		Industry Avg:	21.61%	22.13%	23.17%	N.A.

Notes:

(1) Sourced from Prospectus dated April 8, 2019.

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

(i) Basic Earnings per Share (Rs.) = Restated net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares outstanding during the year.

Earnings per share calculations are in accordance with the notified Ind AS 33 'Earnings per share' notified accounting standard by the Companies (Indian Accounting Standards) Rules of 2015 (as amended).

(ii) Diluted Earnings per Share (Rs.) = Restated net profit after tax and adjustments, attributable for equity shareholders (after adjusting profit impact of dilutive potential equity shares, if any) / the aggregate of weighted average number of Equity shares outstanding during the year and the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

(iii) Net Asset Value Per Equity Share = Net worth as per the Restated Summary Statements / Number of equity shares outstanding as at the end of year/period.

(iv) P/E - Closing Market Price as of relevant fiscal year end / Basic Consolidated EPS

(v) Return on Net Worth (%) = Restated net profit after tax, available for equity shareholders / Restated net worth at the end of the year.

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
23-Apr-19	Informed that Key Managerial Personnels of the Company have been authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosure of such material event or information to the stock exchanges
23-Apr-19	Closure of Trading Window for dealing in the securities of the Company to be closed for all the Directors, Promoters, Designated Employees and Connected Persons with immediate effect i.e., from April 15, 2019
23-Apr-19	Pursuant to the requirement under Regulation 30(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Key Managerial Personnels ("KMPs") of the Company has been authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosure of such material event or information to the stock exchanges
23-Apr-19	Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sushil Kanubhai Shah, Duru Sushil Shah & METZ Advisory LLP
30-Apr-19	Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
2-May-19	Informed that Board of Directors of the Company has made the following changes in the Composition of the Nomination and Remuneration Committee of the Board w.e.f. May 2, 2019. Previous Composition: 1)Mr. Vivek Gambhir - Chairman 2)Mr. Sanjay Bhatnagar - Member 3)Mr. Mihir Jagdish Doshi - Member Changed Composition: 1) Mr. Vivek Gambhir - Chairman 2) Mr. Milind Shirpad Sarwate - Member 3) Mr. Mihir Jagdish Doshi - Member
6-May-19	Compliance Certificate From The Registrar And Share Transfer Agent For Half Year Ended March 31, 2019.
6-May-19	Board Meeting Intimation for To Consider And Approve The Audited Financial Results And The Final Dividend, If Any For The Financial Year Ended March 31, 2019.
7-May-19	Announcement under Regulation 30 (LODR)-Newspaper Publication
13-May-19	Informed that the Board of Directors in their meeting held today i.e. May 13, 2019 approved the audited financial results (Standalone and Consolidated) of the Company for the year ended March 31, 2019.
13-May-19	Intimation for copy of Investor Presentation for Investor Meet to be held on May 14, 2019.
15-May-19	Announcement under Regulation 30 (LODR)-Newspaper Publication
29-May-19	Annual secretarial compliance for the year ended March 31, 2019
12-Jun-19	Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), disclosure on Related Party Transactions in accordance with applicable Accounting Standards.

29-Jun-19	Closure of Trading Window
15-Jul-19	Announcement of Annual Report, Notice of 19th Annual General Meeting, Remote e-voting facility, Scrutinizer and Cut-off date
16-Jul-19	Announcement under Regulation 30 (LODR)-Newspaper Publication
19-Jul-19	Statement Of Investor Complaints For The Quarter Ended June 2019
19-Jul-19	Announcement under Regulation 30 (LODR)-Investor Presentation
30-Jul-19	Intimation for board meeting to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2019
1-Aug-19	Clarification On Recommendations Of Agenda Items Of 19Th Annual General Meeting Of Metropolis Healthcare Limited In Proxy Advisory Report Issued By Stakeholders Empowerment Services (SES)
6-Aug-19	Informed about the Unaudited (Standalone & Consolidated) financial results of the Company for the quarter ended June 30, 2019 and Limited Review Report issued by BSR & Co. LLP.
6-Aug-19	Proceedings of 19th Annual General Meeting of the Company
7-Aug-19	Disclosure Of Voting Results Of AGM (Regulation 44(3) Of SEBI (LODR) Regulations, 2015)
8-Aug-19	Announcement under Regulation 30 (LODR)-Newspaper Publication
20-Aug-19	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
1-Oct-19	Closure of Trading Window
1-Oct-19	Announcement under Regulation 30 (LODR)-Acquisition of 4 laboratories by Desai Laboratories (wholly owned subsidiary)
14-Oct-19	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14-Oct-19	Compliances- Compliance Certificate For The Period Ended September 30, 2019
19-Oct-19	Statement Of Investor Complaints For The Quarter Ended September 2019
22-Oct-19	Certificate Under Regulation 40(9) Of SEBI(LODR)Regulations, 2015 For The Half Year Ended September 30, 2019
31-Oct-19	Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
4-Nov-19	Board Meeting Intimation for Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements)Regulations, 2015
5-Nov-19	Announcement under Regulation 30 (LODR)-Newspaper Publication
11-Nov-19	Outcome of Board Meeting to announce Results- Unaudited Financial Results For 30 September, 2019 (Standalone & Consolidated)
11-Nov-19	Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
11-Nov-19	Announcement under Regulation 30 (LODR)-Press Release / Media Release
11-Nov-19	Announcement under Regulation 30 (LODR)-Investor Presentation
12-Nov-19	Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
12-Nov-19	Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
13-Nov-19	Announcement under Regulation 30 (LODR)-Newspaper Publication
13-Nov-19	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
29-Nov-19	Resignation of Company Secretary and Compliance Officer of the Company
7-Dec-19	Appointment of Interim Compliance Officer
10-12-2019	Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

13-Dec-19	Intimation Of Awards Received Under Regulation 30 Of SEBI (LODR) Regulations 2015.
02-01-2020	Intimation for closure of trading window
16-Jan-20	Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding acquisition of Equity Shares of Shraddha Diagnostic Centre (I) Private Limited.
16-Jan-20	Statement Of Investor Complaints For The Quarter Ended December 2019
30-Jan-20	Board Meeting Intimation for Board Meeting To Be Held On February 06, 2020
31-Jan-20	Announcement under Regulation 30 (LODR)-Newspaper Publication
3-Feb-20	Update on board meeting
3-Feb-20	Fixes Record Date For The Purpose Of Interim Dividend, If Any
3-Feb-20	Board to consider Interim Dividend
6-Feb-20	Unaudited Financial Results For Quarter And Nine Months Ended December 31, 2019
6-Feb-20	Corporate Action-Board approves Dividend
6-Feb-20	Announcement under Regulation 30 (LODR)-Investor Presentation
6-Feb-20	Announcement under Regulation 30 (LODR)-Press Release / Media Release
10-Feb-20	Intimation of appointment of Company Secretary and Compliance Officer
10-Feb-20	Announcement under Regulation 30 (LODR)-Newspaper Publication
13-Feb-20	Intimation Of Awards Received Under Regulation 30 Of SEBI (LODR) Regulations 2015
18-Feb-20	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
6-Mar-20	Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
7-Mar-20	Intimation of Newspaper Publication of Notice of Postal Ballot to Members
24-Mar-20	Informed that the Indian Council of Medical Research (ICMR), vide its notification dated March 23, 2020, has empanelled the Company's Global Reference Lab at Unit No. 409-416, Commercial Building-1, Kohinoor Mall, Vikhroli, Mumbai for Covid -19 testing.
31-Mar-20	Informed that the Board of Directors of the Company has changed the composition of its Audit Committee and Nomination and Remuneration Committee by circular resolution on March 30, 2020
16-Apr-20	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CA Lotus Investments
23-Apr-20	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SMALLCAP World Fund, Inc.
23-Apr-20	Metropolis Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020.
24-Apr-20	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SMALLCAP World Fund, Inc.
30-Apr-20	Informed about Resignation of Mr. Mihir Jagdish Doshi (DIN: 01283331) as a Non-Executive-Non-Independent Director of the Company with effect from April 30, 2020
2-May-20	Informed about Statement Of Investor Complaints For The Quarter Ended March 2020
6-May-20	Submission Of Compliance Certificate - Regulation 7 (3) Of The SEBI (Listing Obligations And Disclosures Requirements), Regulations, 2015
6-May-20	Compliance Certificate For The Half Year Ended On March 31, 2020 Under Regulations 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
14-May-20	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
15-May-20	Appointment Of Ms. Anita Ramachandran As An Additional Director(Non-Executive Independent) Under The Category Of Women Independent Director On Board Of The Company.

17-May-20	Press release on the following topic: 'Metropolis Healthcare extends a helping hand to stranded Mauritius citizens'
25-May-20	Informed that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 29, 2020 to inter-alia consider and approve the Audited Standalone and Consolidated Financial statements of the Company for the quarter and financial year ended March 31, 2020.
29-May-20	The Board of Directors of the Company at their meeting held today have inter-alia: 1. Approved the Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2020 2. Approved re-appointment of Dr. Sushil Shah as a Whole-Time Director of the Company, for a period of five years with effect from September 4, 2020, subject to the approval of the members of the Company at the ensuing Annual General Meeting 3. Authorised the Company Officials to determine the materiality of events as prescribed under Regulation 30 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
29-May-20	Announced Financial Results For The Quarter And Year Ended March 31, 2020
29-May-20	Re-Appointment Of Dr. Sushil Shah As A Whole Time Director Of The Company For A Period Of Five Years With Effect From September 4, 2020
29-May-20	Announcement Under Regulation 30 Of The SEBI (LODR), Regulations, 2015 - Impact Of COVID-19 On The Operations Of The Company
30-May-20	Informed that on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have at their meeting held on May 29, 2020, approved the grant of 2,06,700 Restricted Stock Units pursuant to the Metropolis - Restrictive Stock Unit Plan - 2020 to the eligible employees of the Company / Subsidiary(ies).
30-May-20	Addendum To Voting Results Of Postal Ballot Submitted On April 8, 2020
30-May-20	Re-Grant Of Options Under Metropolis Employees Stock Options Scheme, 2015 ('MESOS 2015') Out Of Lapsed Options
11-Jun-20	Non-Applicability Of SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26, 2018 ('The Circular')
24-Jun-20	Informed that a member of the Promoter Group of the Company has divested 3,054,545 equity shares of the Company constituting 6.03% of the issued and paid-up share capital of the Company through a bulk deal transaction on the Stock Exchanges today.
26-Jun-20	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Duru Sushil Shah
26-Jun-20	Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019; we are enclosing herewith the Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2020, issued by M/s. Manish Ghia & Associates, Practicing Company Secretaries.
26-Jun-20	Disclosures Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
26-Jun-20	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Sushil Kanubhai Shah & Others
27-Jun-20	Submission Of Revised Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
30-Jun-20	Informed that pursuant to the Company's Code of Fair Disclosure of Unpublished Price Sensitive Information framed pursuant to the Securities and Exchange Board of India (Prevention of Insider Trading) Regulations, 2015, as amended, the Trading window for dealing in securities of the Company by the Designated Persons of the Company and / or their immediate relatives will be closed with effect from July 1, 2020 and shall remain closed up to 48 (Forty Eight) hours after the declaration of the Financial Results of the Company for the quarter ended June 30, 2020.
2-Jul-20	The Company vide letter dated 16th January, 2020 informed the Exchange(s) regarding the decision of Company to acquire 51% stake at a consideration of Rs.9,36,30,000/- in Shradha Diagnostic Centre (I) Private Limited from its Promoters (Seller) vide Shareholders' Agreement and Share Purchase dated 16th January, 2020 entered between the Company, SDCIPL and its promoters. The closure of transaction was subject, to certain conditions precedent as specified in the Share Purchase Agreement (SPA) to be fulfilled on or before the amended long stop date, as per the supplemental share purchase agreement. The promoters of SDCIPL have conveyed that they cannot fulfil certain conditions precedent due to which the closing could not be completed, which is a breach of Warranty. Therefore, the promoters of SDCIPL have communicated to the Company their intent to terminate the said SPA and accordingly the proposed acquisition stands closed.
14-Jul-20	Statement Of Investor Complaints For The Quarter Ended June 2020
15-Jul-20	Intimation For Change In Composition Of Corporate Social Responsibility Committee And Nomination And Remuneration Committee

16-Jul-20	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vistra ITCL India Ltd
16-Jul-20	The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 19, 2020 for Dr. Sushil Kanubhai Shah
20-Jul-20	The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 19, 2020 for Dr. Duru Sushil Shah
20-Jul-20	Metropolis Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020.
5-Aug-20	Metropolis Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2020, inter alia, to consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the Quarter ended June 30, 2020.
6-Aug-20	Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, a copy of the Newspaper advertisement with respect to the notice of the Board Meeting scheduled to be held on Tuesday, August 11, 2020, published in the following newspapers on August 6, 2020:
11-Aug-20	Informed on Outcome Of The Board Meeting Held On August 11, 2020
12-Aug-20	Submission of copy of Newspaper Advertisement dated August 11, 2020 under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
19-Aug-20	In compliance with the provisions of Companies Act, 2013 and MCA Circular No. 20/2020 dated May 5, 2020 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the 20th Annual General Meeting (AGM) of the Company is scheduled to be held on Wednesday, September 16, 2020 through Video Conference/Other Audio Visual Means (VC/OAVM).
19-Aug-20	Pursuant to Regulation 30, 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein enclose copy of newspaper Advertisement published in Free Press Journal (English Newspaper) and Navshakti (Marathi Newspaper) on August 20, 2020 intimating that the 20th Annual General Meeting of the Company will be held through Video Conferencing / Other Audio Visual Means on Wednesday, September 16, 2020 at 9:00 a.m. IST.
20-Aug-20	With reference to the captioned subject, our earlier letter dated August 19, 2020 having reference no. MHL/Sec&Legal/2020-21/128 wherein we had informed the Exchange about the 20th Annual General Meeting ('AGM') of the Company. In continuation to the same and as required under Regulations 30, 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Annual Report of the Company for the Financial Year 2019-2020 along with the Notice convening the 20th AGM of the Company scheduled to be held on Wednesday, September 16, 2020 at 9:00 A.M. (IST) through Video Conferencing / Other Audio Visual Means (VC / OAVM) in compliance with the General Circular No. 14/2020 dated
24-Aug-20	Notice Convening 20Th Annual General Meeting Of The Company
16-Sep-20	Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the 20th Annual General Meeting (AGM) of the Company was held on Wednesday, September 16, 2020 at 9:00 a.m. (IST) through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') in accordance with the circular(s) issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.
18-Sep-20	Metropolis Healthcare Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015.
30-Sep-20	This is to inform you that pursuant to the Company's Code of Fair Disclosure of Unpublished Price Sensitive Information framed pursuant to the Securities and Exchange Board of India (Prevention of Insider Trading) Regulations, 2015, as amended, the Trading window for dealing in securities of the Company by the Designated Persons of the Company and / or their immediate relatives will be closed with effect from October 1, 2020 and shall remain closed up to 48 (Forty-Eight) hours after the declaration of the Financial Results of the Company for the quarter ended September 30, 2020. The date of the Board meeting for approval of financial results of the Company for the quarter ended September 30, 2020 shall be intimated in due course.
1-Oct-20	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that CRISIL, a Credit Rating Agency has reaffirmed its 'CRISIL AA-/Stable' rating on the Non-Convertible Debentures and the long-term loan facility of the Company and has also reassigned its 'CRISIL A1+' rating to the short-term bank facility of the Company. Further, please note that the Company has neither issued the Non-Convertible Debentures nor availed the long-term or short-term bank facility as aforesaid till date.
5-Oct-20	In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, we would like to update on the key business parameters of the Company for the quarter ended September 30, 2020 as per the intimation attached.
9-Oct-20	Pursuant to the requirements of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, please find enclosed herewith the Compliance Certificate for the half-year ended September 30, 2020, duly signed by the Authorized Representative of the Registrar and Share Transfer Agent of the Company and the Company Secretary and Compliance Officer of the Company.
13-Oct-20	Statement Of Investor Complaints For The Quarter Ended September 2020
13-Oct-20	Metropolis Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020.
20-Oct-20	Pursuant to Regulation 40 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Compliance Certificate dated October 20, 2020 issued by Mr. Manish L. Ghia of M/s. Manish Ghia & Associates, Practicing Company Secretaries for the half year ended September 30, 2020.
5-Nov-20	Announcement under Regulation 30 (LODR)-Press Release / Media Release
5-Nov-20	With reference to the captioned subject, our earlier intimation dated August 11, 2020 having reference no. MHL/Sec&Legal/2020-21/121 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that the Company has successfully acquired the balance stake of 49% in Raj Metropolis Healthcare Private Limited.
5-Nov-20	Metropolis Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2020, inter alia, to consider and approve We wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 11, 2020 through Video Conferencing to inter-alia consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the Quarter and Half-year ended September 30, 2020.
6-Nov-20	Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, a copy of the Newspaper advertisement with respect to the notice of the Board Meeting scheduled to be held on Wednesday, November 11, 2020, published in the following newspapers on November 6, 2020: 1. Free Press Journal (English, Mumbai Edition) 2. Navshakti (Marathi, Mumbai Edition) You are requested to take the above information on record.

7-Nov-20	<p>This is to inform you that the Board of Directors of the Company on November 11, 2020 approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and half-year ended September 30, 2020.</p> <p>In this regard and pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein enclose the copy of the Newspaper Advertisement dated November 11, 2020 published in the following newspapers:</p>
9-Nov-20	Metropolis Healthcare wins the 'Diagnostic Company of the Year Award' organized by Frost & Sullivan
11-Nov-20	Submission of Unaudited Standalone and Consolidated financial results along with the Limited Review report for the quarter and half-year ended September 30, 2020
12-Nov-20	<p>Informed that the Board of Directors of the Company on November 11, 2020 approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and half-year ended September 30, 2020.</p> <p>In this regard and pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein enclose the copy of the Newspaper Advertisement dated November 11, 2020 published in the following newspapers:</p> <ol style="list-style-type: none"> 1. Free Press Journal (English) 2. Navshakti (Marathi)
12-Nov-20	<p>Informed that the Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held today has:</p> <ol style="list-style-type: none"> 1. Approved the allotment of 1,77,887 (One Lakh Seventy Seven Thousand Eight Hundred and Eighty Seven) Equity Shares of Rs. 2/- (Rupees Two Only) each 2. Approved the grant of 22,750 Restricted Stock Units pursuant to the Metropolis - Restrictive Stock Unit Plan - 2020 (MHL - RSU Plan 2020) to the eligible employees of the Company / Subsidiary(ies).
9-Dec-20	Disclosures Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
31-Dec-20	Statement Of Investor Complaints For The Quarter Ended December 2020
31-Dec-20	Informed about Closure of Trading Window
9-Jan-21	Shareholding for the Period Ended December 31, 2020
12-Jan-21	Metropolis Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/01/2021, inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Sunday January 17, 2021.
17-Jan-21	Informed on Outcome of Board meeting held on Sunday, January 17, 2021
17-Jan-21	Announcement under Regulation 30 (LODR) on acquisition Dr. Ganesan's Hitech Diagnostic Centre Private Limited and its subsidiary ('Hitech') from its existing promoters / shareholders

19-Jan-21	Notice Of Postal Ballot
20-Jan-21	In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, enclosed a Business Update on the key business parameters of the Company on a Consolidated basis for the quarter ended December 31, 2020 i.e. Q3FY21
20-Jan-21	Pursuant to Regulation 30 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of Newspaper Advertisement dated January 19, 2021 published in the following newspapers: 1. Free Press Journal (English) 2. Navshakti (Marathi)
28-Jan-21	Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
4-Feb-21	Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On Wednesday, February 10, 2021
4-Feb-21	Intimation Of Record Date For Interim Dividend
4-Feb-21	Informed that a meeting of the Board of Directors of the Company ('the Board') is scheduled to be held on Wednesday, February 10, 2021 through Video Conferencing to inter-alia: Consider the proposal for declaration of an Interim Dividend for the Financial Year 2020-2021.
5-Feb-21	Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith a Press Release to be issued by the Company. This is for your information and records.
10-Feb-21	Informed that the Board of Directors of the Company at their meeting held today have approved the re-appointment of Ms. Ameera Sushil Shah as the Managing Director, for a period of five years with effect from March 18, 2021, as per the recommendation of the Nomination and Remuneration Committee, subject to approval of members of the Company at the ensuing Annual General Meeting.
10-Feb-21	Enclosed a copy of the Investor Presentation for the quarter and nine months ended December 31, 2020.
10-Feb-21	Announcement under Regulation 30 (LODR)-Press Release / Media Release
10-Feb-21	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

11-Feb-21	<p>Informed that the Board of Directors of the Company on February 10, 2021 approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020.</p> <p>In this regard and pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein enclose the copy of the Newspaper Advertisement dated February 10, 2021 published in the following newspapers:</p>
17-Feb-21	<p>Informed that with reference to the Postal Ballot Notice dated January 19, 2021 issued pursuant to Section 110 of the Companies Act, 2013 for seeking approval of the members of the Company by means of Postal Ballot including voting by electronic means for exercising their votes in respect of such resolutions as set out in the said Postal Ballot Notice. In this regard, for the sake of clarity in the language in Point 20 (a) of Item No. 2 of the Explanatory Statement, please find enclosed a Corrigendum to the Postal Ballot Notice published in the following newspapers:</p> <ol style="list-style-type: none"> 1. Free Press Journal (English) 2. Navshakti (Marathi)
20-Feb-21	<p>informed that the following resolutions have been passed by the members of the Company by requisite majority on February 18, 2021, being the last date for remote E-voting:</p> <ol style="list-style-type: none"> 1. Approval for increase in limit to provide loan, guarantee or security in respect of loan to any person or Body Corporate or to make investment in any other Body Corporate. 2. To issue, offer and allot equity shares on a Preferential Basis. <p>In this regard, we herein submit the details of the Voting results as 'Annexure A' and the Scrutinizer's report dated February 19, 2021 received by the Company on February 20, 2021 as 'Annexure B' for the Postal Ballot process conducted by the Company.</p>
22-Feb-21	<p>Metropolis Healthcare Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015.</p>
4-Mar-21	<p>The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sushil Shah Family Trust & PACs</p>
4-Mar-21	<p>The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Veer Singh & PAC</p>
4-Mar-21	<p>The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Duru Shah Family Trust</p>
5-Mar-21	<p>The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Duru Shah Family Trust & PACs</p>
9-Mar-21	<p>The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 09, 2021 for Metz Advisory LLP</p>
30-Mar-21	<p>Announcement under Regulation 30 (LODR)-Press Release / Media Release</p>

9-Apr-21	Announcement Under Regulation 30 Of SEBI (LODR) : Quarterly Business Update Q4FY21
10-Apr-21	Compliance Certificate Under Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half-Year Ended March 31, 2021
10-Apr-21	Statement Of Investor Complaints For The Quarter Ended March 2021
12-Apr-21	Compliance Certificate Pursuant To Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
15-Apr-21	In continuation to our earlier intimation having reference no. MHL/Sec & Legal/2020-21/161 dated January 17, 2021 pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, wherein we had informed that the indicative time period for the completion of acquisition of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech') would be three months (3 months) from January 17, 2021. With regard to same, we wish to inform you that due to the current situation of COVID-19 pandemic and as mutually agreed between both the parties, the aforementioned acquisition would be closed and completed within next 45 days.
20-Apr-21	Metropolis Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021.
28-Apr-21	With reference to the SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November, 2018 in respect of fund raising by issuance of Debt Securities by Large Entity and disclosures and compliances thereof by such Large Corporate (LC). In this connection, we hereby submit that Metropolis Healthcare Limited does not fall under the Large Corporate (LC) category as per framework provided in the aforesaid Circular.
21-May-21	Metropolis Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2021, inter alia, to consider and approve the Audited Standalone & Consolidated Financial Results of the Company for the year ended March 31, 2021.
27-May-21	Outcome of Board Meeting dated May 27, 2021
27-May-21	The Board approved the appointment of Mr. Hemant Sachdev as an Additional Non-Executive Non-Independent Director of the Company, who shall hold office till the date of the forthcoming Annual General Meeting and shall continue to hold office thereafter, subject to the approval of the

27-May-21	Board has accepted and took on record the resignation of Ms. Poonam Tanwani from the post of Company Secretary and Compliance Officer of the Company with effect from close of business hours of May 31, 2021 and approved the appointment of Mr. Danish Allana, Associate Company Secretary (having membership no. A61517) as an Interim Compliance Officer of the Company with effect from June 1, 2021.
27-May-21	Announcement under Regulation 30 (LODR)-Press Release / Media Release
27-May-21	The Board has approved the re-constitution of the Risk Management Committee.
27-May-21	The Nomination and Remuneration Committee at its meeting held today has approved : a. the allotment of 12,100 equity shares of Face Value Rs. 2 each of the Company to the eligible employees; b. the grant of 2,000 RSU"s to the eligible employees of the Company
28-May-21	This is to inform you that the Board of Directors of the Company on May 27, 2021 approved the Audited Standalone and Consolidated Financial Statements of the Company for the quarter and year ended March 31, 2021. In this regard and pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein enclose the copy of the Newspaper Advertisement dated May 27, 2021 published in the following newspapers: 1. Free Press Journal (English) 2. Navshakti (Marathi)
29-May-21	In continuation to our earlier intimation having reference no. MHL/Sec & Legal/2021-22/5 dated 14.04.2021 pursuant to Regulation 30 of the SEBI(LODR) Regulations, 2015, wherein we had informed that due to the COVID19 pandemic and as mutually agreed between both the parties, the acquisition of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech') along with its subsidiary Centralab Healthcare Services Private Limited would be closed and completed by the Company within 45 days from April 14, 2021. We wish to inform the Exchanges that the family of the selling shareholders i.e. promoters and shareholders of Hitech are in poor health due to COVID complications, since a month coupled with the lockdown imposed in Chennai, due to which the completion of the aforementioned acquisition has got delayed. The Company is making its best efforts to close the transaction and wherever required, it will seek necessary approval of the authorities and will update the Exchanges on the same
24-Jun-21	Submission Of Related Party Transactions On A Consolidated Basis.
28-Jun-21	Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2021
30-Jun-21	Closure of Trading Window

5-Jul-21	Announcement Under Regulation 30 Of SEBI (LODR) - Intimation Of Date Of AGM
8-Jul-21	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
10-Jul-21	Announcement Under Regulation 30 Of SEBI (LODR) - Updates On Acquisition
14-Jul-21	Statement Of Investor Complaints For The Quarter Ended June 2021
15-Jul-21	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
18-Jul-21	Notice Convening 21St AGM Of The Company
19-Jul-21	Metropolis Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021
31-Jul-21	Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On Friday, August 6, 2021
6-Aug-21	Outcome of the Board meeting held on August 06, 2021

6-Aug-21	Financial Results For The Quarter Ended June 30, 2021
6-Aug-21	The Board of Directors approved the appointment of Ms. Simmi Singh Bisht having Membership Number ACS 23360 as the Company Secretary and Compliance Officer of the Company (designated as Head - Legal and Secretarial) with effect from August 6, 2021 and took note of the cessation of Mr. Danish Allana as the Interim Compliance Officer of the Company with effect from August 6, 2021
6-Aug-21	The Board of Directors approved the Scheme of merger by absorption of Bokil Golwilkar Metropolis Healthcare Private Limited and Desai Metropolis Health Services Private Limited and Dr. Patel Metropolis Healthcare Private Limited and Lab One Metropolis Healthcare Services Private Limited and Micron Metropolis Healthcare Private Limited and R.V. Metropolis Diagnostic & Health Care Center Private Limited and Raj Metropolis Healthcare Private Limited and Sudharma Metropolis Health Services Private Limited ('Transferor Companies') with the Company and their respective Shareholders ('Scheme') under the provisions of sections 230 to 232 of the Companies Act, 2013 subject to requisite consents / approvals.
6-Aug-21	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
6-Aug-21	Announcement under Regulation 30 (LODR)-Press Release / Media Release
11-Aug-21	Announcement under Regulation 30 (LODR)-
12-Aug-21	Enclosed herewith are the voting results and the scrutinizer's report for the resolutions passed at the 21st Annual General Meeting of the Company held on August 11, 2021
12-Aug-21	Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
30-Sep-21	Informed that, the Trading window for dealing in securities of the Company by the Designated Persons of the Company and / or their immediate relatives will be closed with effect from October 1, 2021 and shall remain closed up to 48 (Forty Eight) hours after the declaration of the Financial Results of the Company for the quarter and half year ended September 30, 2021.

11-Oct-21	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
12-Oct-21	Submitted Statement Of Investor Complaints For The Quarter Ended September 2021
14-Oct-21	Submitted Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15-Oct-21	Outcome of the Board meeting held on October 15, 2021
18-Oct-21	Metropolis Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021.
20-Oct-21	Announcement under Regulation 30 (LODR)-Credit Rating
22-Oct-21	Informed you that Metropolis Healthcare Limited ('the Company') has completed the acquisition of 100% stake of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech') along with its subsidiary Centralab Healthcare Services Private Limited ('Centralab') on October 22, 2021 for a cash consideration of Rs.636 Crores (Six Hundred and Thirty-Six Crores Only) as per the terms and conditions of the Share Purchase Agreement including amendments thereof entered between the Company and the sellers.
22-Oct-21	Announcement under Regulation 30 (LODR)-Press Release / Media Release
2-Nov-21	Board Meeting Intimation for Quarterly Results For The Quarter Ended September 30, 2021

9-Nov-21	Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
10-Nov-21	Board Meeting Outcome for Outcome Of The Board Meeting Held On November 10, 2021
10-Nov-21	Announcement under Regulation 30 (LODR)-Investor Presentation
10-Nov-21	Announcement under Regulation 30 (LODR)-Press Release / Media Release
10-Nov-21	Grant Of Rsus Pursuant To The Metropolis - Restrictive Stock Unit Plan - 2020 (MHL - RSU Plan 2020)
11-Nov-21	Announcement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-21	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
18-Nov-21	Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
19-Nov-21	Announcement under Regulation 30 (LODR)-Earnings Call Transcript

23-Nov-21	The Exchange has received the revised disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Grandeur Peak Global Advisors, LLC
29-Nov-21	Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
30-Nov-21	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SMALLCAP World Fund, Inc.
2-Dec-21	The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SMALLCAP World Fund, Inc
31-Dec-21	Closure of Trading Window
5-Jan-22	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
12-Jan-22	Shareholding for the Period Ended December 31, 2021
12-Jan-22	Statement Of Investor Complaints For The Quarter Ended December 2021
13-Jan-22	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

3-Feb-22	Intimation Of Record Date For Interim Dividend
3-Feb-22	Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On Friday, February 11, 2022
3-Feb-22	Corporate Action-Board to consider Dividend
9-Feb-22	Informed that pursuant to the approval of the Board of Directors through Circular Resolution passed on January 14, 2022, the Company has transferred on February 09, 2022, 100 (Hundred) Equity Shares of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech') (Wholly owned subsidiary of the Company) to Amin's Pathology Laboratory Private Limited ('Amin's'), a wholly-owned subsidiary of the Company, at a total consideration of Rs. 1,97,333/- (Rupees One Lakh Ninety-Seven Thousand Three Hundred and Thirty-Three Only). Accordingly, post transfer of said Equity Shares of Hitech, the direct holding of the Company in Hitech stand at 99.99% and the balance stake will be held through Amin's, a wholly owned subsidiary of the Company
11-Feb-22	Financial Results For The Quarter And Nine Months Ended December 31, 2021
11-Feb-22	Corporate Action-Board approves Dividend
11-Feb-22	Announcement under Regulation 30 (LODR)-Press Release / Media Release
11-Feb-22	Announcement under Regulation 30 (LODR)-Investor Presentation
11-Feb-22	Grant Of Restrictive Stock Units ('RSU'S') Under Metropolis - Restrictive Stock Unit Plan, 2020 ('MHL-RSU Plan, 2020')

12-Feb-22	Corrigendum - Limited Review Report On The Unaudited Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2021.
12-Feb-22	Submission of copy of Newspaper Advertisement dated February 12, 2022
22-Feb-22	The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Sushil Kanubhai Shah
24-Feb-22	Transcripts of Earning Call for Q3FY2022

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com.

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement.